pexidartinib — CareFirst (Caremark)

Initial criteria

• Used as a single agent.
• Member has a colony stimulating factor 1 receptor (CSF1R) mutation.
• Disease is symptomatic or relapsed/refractory.

Reauthorization criteria

• No evidence of unacceptable toxicity or disease progression while on the current regimen.

Approval duration

12 months